Outsmarting Cancer, Impacting lives

Working between IP and business development, Eline supports researchers in protecting and developing their ideas.

When a drug screen in organoids pointed us towards a new drug combination against a subtype of colorectal cancer, we wanted to test it in patients. The journey from lab to clinic took ten years, three disciplines, and a risk-tolerant funding model. It led us to an unexpected destination.

Oncode Institute today announces the launch of the Oncology Bridge Fund II (OBF II), in collaboration with Ligase BioPartners, building on their established partnership in the first Oncology Bridge Fund (OBF I). This fund signals a next step, in scaling up Oncode Institute’s valorisation efforts, accelerating  translation of breakthrough cancer research into societal, clinical and patient impact.